Companies category powered by

ILIKOS Consulting Group and Phoenix Clinical Research announce strategic partnership

Cyprus-based ILIKOS Consulting Group earlier this month announced the start of a strategic partnership with Phoenix Clinical Research, which has its head office in Beirut, Lebanon.

"Leveraging our geographical location and extensive network of partners to promote clinical research in the MENA/GCC regions has been a key driver of our vision. Phoenix Clinical Research is a reliable and highly experienced service provider working closely with study Sponsors worldwide to execute studies in these promising regions," said Elias Sayias BSc. CCRA, Founder and CEO of ILIKOS commented in a press release on the partnership.

"Our close collaboration aims to bridge geographical, linguistic and cultural gaps enabling study Sponsors to benefit from access to a diverse population of Patients in numerous therapeutic areas. In turn, this will help them advance their development strategies and reach key milestones," he continued.

Phoenix Clinical Research: An ambassador for the MENA & GCC regions

According to the same press release, “Boasting significant expertise and meaningful relationships across numerous countries, Phoenix offers a unique value proposition combining Patient access to a wide range of chronic, acute and rare indications with high quality. Phoenix works closely with study Sponsors across all phases of development to mitigate risk, develop and establish realistic strategies while minimizing regulatory hurdles, linguistic challenges, geopolitical turbulence, and operational gaps.”

"I founded Phoenix CR as I wanted to create a healthy work-life balance environment; and a nurturing ecosystem cultivating the immense potential and talent of human resources in our region. As an ambassador for our Clients in the MENA & GCC regions, we enable streamlined communication mitigating linguistic gaps, clear understanding of processes and timelines along with reliable solutions across all development phases. Our foundational drivers are driven by: access to advanced medical expertise, a strong network of high performing research sites and effective Patient recruitment," commented Dr. George Labaki, CEO of Phoenix, within the same announcement.

About ILIKOS Consulting Group

According to the press release, ILIKOS offers flexible, adaptive and highly personalized consulting services to biopharmaceutical and medical technology companies helping them progress the development of their investigational products. ILIKOS also works closely with a wide range of Contract Research Organizations (CROs) to establish and execute highly effective business & corporate development strategies.

To learn more, please visit: www.goilikos.com

About PHOENIX Clinical Research

Also according to the press release, Phoenix Clinical Research is a regional dynamic full-service Contract Research Organization (CRO) established in Lebanon. Its objective is to cover the whole Middle East and North Africa region. From clinical operations to medical writing and biostatistics, Phoenix delivers top quality services driven by core values of Transparency, Quality, Commitment and Efficiency, building trust by appropriately sharing information and having open communications with stakeholders.

To learn more, please visit: https://phoenix-cr.com/

Read More

Fitch upgrades Hellenic Bank's Shareholder Support Rating to 'bb'
Ad and communication agencies Red Wolf and Ogilvy Cyprus to merge
US experts in Cyprus as part of ongoing partnership in fight against illicit financial activity
MultiCare Elite by Universal Life: Unparalleled Medical Coverage in Cyprus
ASBIS Kypros Ltd celebrates its 20th anniversary
Every Step Counts: Fundraising Challenge for paediatric cancer research
Ariston patisserie closing Griva Digeni location after six decades, opening new store in Engomi
Cyprus' Minister of Education outlines roadmap for AI integration in education
Corruption and cost of energy the most serious problems, President Christodoulides says
Cyprus’ job vacancy rate remains at 3.0% in Q2 2024